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ABSTRACT
Objective: Epilepsy is the second most common neurologic disorder after stroke. The study was undertaken to determine the prevalence of epilepsy 
disorders and drug utilization pattern in a patient population of Dehradun. This study was conducted in a private health clinic.
Methods: A questionnaire was prepared that includes many practical questions regarding epilepsy seizure type, medication prescribed, their health 
status, and compliance. A total of 200 cases of epilepsy were reported.
Results: The study showed the prevalence of epilepsy disorders which was most common among males (65%) as compared to females (35%). 44% 
of epilepsy disorders were found prevalent among the age group between 30 and 40 years. The most common type of epilepsy disorder is primary 
generalized seizure (62%) followed by partial seizures (23%), focal disorder (6%), grand mal cortical focal epilepsy (5%), typical seizures (3.5%), 
refractory seizures (3%), and others (2.5%).
Conclusion: Epilepsy is one of the most serious neurological disorders in terms of both prevalence and cumulative incidence. Good education and 
counseling is required for coping up the challenges of this condition as well for improving patient compliance. For decreasing the chances of adverse 
effects and avoiding drug interactions monotherapy is important. Health-care providers and patients can together formulate a better therapeutic plan 
for achieving a seizure-free status without adverse effects.
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INTRODUCTION
About 10% of people will have one seizure in their lifetime and about 
a third of them will go on to develop epilepsy [1,2]. It is a disorder that 
can occur in all mammalian species, probably more frequently as brain 
has become more complex and also remarkably uniformly distributed 
around the world. There are no racial, geographical or social class 
boundaries, it occurs in both sexes, at all ages, especially in childhood, 
adolescence and increasingly in ageing populations [3,4]. About 10% 
epileptic seizures may cause convulsions if the motor cortex is involved. 
The seizures may involve visual, auditory, or olfactory hallucinations if 
the parietal and occipital cortex plays a role.
Although drug therapy is the most widely effective mode for the 
treatment of epilepsy, it is not hundred percent effective in all patients. 
For example, it is frequently hindered by poor patient adherence, and 
often it is complicated by drug interactions. However, seizures can be 
controlled completely in approximately 50% of epileptic patients and 
a meaningful improvement is achieved in at least half of the remaining 
patients. An epileptic seizure is a transient paroxysm of uncontrolled 
discharges of neurons causing an event that is discernible by the 
person experiencing the seizure and/or by an observer. The tendency 
to have recurrent attacks is known as epilepsy; by definition a single 
attack does not constitute epilepsy. A patient with epilepsy will 
show recurrent epileptic seizures that occur unexpectedly and stop 
spontaneously [5,6].
Epilepsy has a focal origin in the brain. It manifests from the site of the 
focus, regions into which the discharges spread. Most of the cases are 
primary (idiopathic), some may be secondary to trauma/surgery on 
head, intracranial tumor, tuberculoma, cysticercosis, cerebral ischemia, 
etc. Epilepsies have been classified variously: Major types are given in 
Table 1 [4].
Treatment of epilepsies
Antiepileptic drugs suppress seizures but do not cure the disorder; the 
disease may fadeout though after years of successful control. Control 
and prevention of all seizure activity is the aim of antiepileptic drugs 
at an acceptable level of side effects. Selection of an anticonvulsant 
medication depends on an accurate diagnosis of the epileptic syndrome. 
Some anticonvulsants (e.g., lamotrigine, topiramate, and valproic 
acid) have multiple mechanisms of action and some (e.g., phenytoin 
and carbamazepine) have only one known mechanism of action, 
anticonvulsant agents can be divided into large groups based on their 
mechanisms are given in Table 2 [6].
METHODS
The study has been conducted to observe the prevalence and drug 
utilization pattern in epileptic patients in a private health clinic. The 
main objectives include investigation of the prevalence of epilepsy 
disorders, types, determination of gender wise and age wise distribution 
of epileptic patients and observation of their drug utilization pattern. 
This study included 200 subjects, after informing them about the 
purpose of the study and prior consent. A questionnaire was prepared 
that includes many practical questions regarding disease condition, 
medication prescribed, health status, and patient compliance. Table 3 
shows the questions which were asked from the epileptic patient.
RESULTS
This study included 200 epileptic patients among which 130 (65%) 
were males and 70 (35%) were females (Fig. 1). The age wise 
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distribution of epilepsy disorders showed that 44% of disorders were 
prevalent among age group between 30 and 40 years (Fig. 2). This 
study highlighted that primary generalized seizures (62%) were most 
common among the concerned epileptic patients (Fig. 3).
Table 4 shows the type of epilepsy disorders among male and female 
patients and their total percentage of prevalence. Grand mal epilepsy 
(66%) is the major type of generalized seizures prevalent among male 
patients. Table 5 shows the antiepileptic drugs given for a particular 
type of epilepsy disorders. Benzodiazepine, phenytoin, and valproate 
are the most commonly prescribed drugs categories. It was also 
found that some other drugs were prescribed such as Aciloc and 
multivitamins, along with antiepileptic drugs. This study also revealed 
that 04% of patients in the age group 60-70 years were noncompliant 
for their medication due to given reasons such as faces difficulty in 
swallowing, forget to take medicines, and poor economic status.
DISCUSSION AND CONCLUSION
The goal of treatment is to achieve a seizure-free status without 
adverse effects. Monotherapy is important, because it decreases the 
likelihood of adverse effects and avoids drug interactions. Adaption of 
treatment decisions to the characteristics of the individual is the key 
to optimum epilepsy management. Antiepileptic drugs monotherapy 
is indicated after two seizures, but in high-risk patients initiation of 
treatment after one seizure might be justifiable. Dose titration and 
Table 1: Classification of major types of epilepsy [4]
Types Description
Generalized seizures
GTCS, major epilepsy, grand mal epilepsy It is the most common disorder, lasts 1-2 min. Aura-cry- unconsciousness-tonic 
spasm of all body muscles- clonic jerking followed by prolonged sleep and 
depression of all CNS functions
Absence seizures (minor epilepsy, petit mal) It last about ½ minute, prevalent in children
Momentary loss of consciousness, patient apparently freezes and stares in one 
direction, no muscular component or little bilateral jerking. EEG shows characteristic 
3 cycles per second spike and wave pattern
Atonic seizures (Akinetic epilepsy) Unconsciousness with relaxation of all muscles due to excessive inhibitory 
discharges patient may fall
Myoclonic seizure Shock like momentary contraction of muscles of limb or the whole body
Infantile spasms (hypsarrhythmia) Seen in infants. Probably not a form of epilepsy. Intermittent muscles spasm and 
progressive mental deterioration. Diffuse changes in the inter seizure EEG are noted
Partial seizures
SPS, cortical focal epilepsy Often secondary, last ½-1 minute. Convulsion are confined to a group of muscles 
or localized sensory disturbance depending on the area of cortex involved in the 
seizure, without loss of consciousness
CPS, temporal lobe epilepsy, psychomotor Attacks of bizarre and confused behavior and purposeless movements, emotional 
changes lasting 1-2 minutes along with impairment of consciousness. An aura often 
proceeds. The seizure focus is located in the temporal lobe
Simple partial or complex partial seizures secondarily 
generalized
The partial seizure occurs first and evolves into generalized tonic-clonic seizures with 
loss of consciousness
GTCS: Generalized tonic-clonic seizures, SPS: Simple partial seizure, CPS: Complex partial seizures
Table 2: Anticonvulsant drugs with their mechanism of action
Mechanism of action Drugs
Blockers of repetitive activation of the sodium channel Phenytoin, carbamazepine, oxcarbazepine, lamotrigine, topiramate
Enhancer of slow inactivation of the sodium channel Lacosamide, rufinamide
GABA-A receptor enhancers Phenobarbital, benzodiazepines, clobazam
NMDA receptor blockers Felbamate
AMPA receptor blockers Perampanel, topiramate
T-calcium channel blockers Ethosuximide, valproate
N- and L-calcium channel blockers Lamotrigine, topiramate, zonisamide, valproate
H-current modulators Gabapentin, lamotrigine
Blockers of unique binding sites Gabapentin, levetiracetam
Carbonic anhydrase inhibitors Topiramate, zonisamide
Neuronal potassium channel (KCNQ [Kv7]) opener Ezogabine
GABA: Gamma-aminobutyric acid
Fig. 1: Gender wise distribution of epileptic patients
Table 3: Questionnaire
Questions were asked regarding
Types of epilepsy disorders
Medication prescribed
Patient compliance for medication
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dosing regimens also need to be carefully individualized. Combination 
therapy can be beneficial in patients who did not respond to two 
or three sequential monotherapy, although in some cases earlier 
institution of polytherapy might be justified. The clinical signs 
and symptoms of seizures depend on the location of the epileptic 
discharges in the cerebral cortex and the extent and pattern of the 
propagation of the epileptic discharge in the brain. A key feature of 
epileptic seizures is their stereotypic nature.
Table 4: Epilepsy types and their percentage of prevalence among male and female
Type Male (n=130) Female (n=70) Total (n=200) Percentage (n=200)
Primarily generalized seizures 90 34 124 62
Grand mal epilepsy 66 22 88 44
Status epilepticus 08 03 11 5.5
Infantile spasm 04 02 06 3
Myoclonic seizures 04 03 07 3.5
Atonic seizures 02 - 02 1
Petit mal epilepsy 06 04 10 5
Partial seizures 14 12 26 13
CPS 14 04 18 9
SPS - 08 08 4
Focal disorder 10 02 12 6
Refractory seizures - 06 06 3
Grand mal cortical focal epilepsy 08 02 10 5
Cebrile convulsions - 05 05 2.5
General dilation of ventricles 05 - 05 2.5
Head injury - 05 05 2.5
Typical seizure 03 04 07 3.5
CPS: Complex partial seizures, SPS: Simple partial seizures
Fig. 2: Age wise distribution of epileptic patients
Table 5: Drug treatment given to epileptic patients
Disease Antiepileptic drugs Other drugs given
Status epilepticus Phenytoin (phenytal), valproate (valvorin), carbin SR (carbamazepine) 
cecozam (diazepam)
-
GTCS Carbamazepine - SR, secozam (diazepam), clobazam (clonazepam), 
calmpose (diazepam), serpex (oxazepam)
Aciloc multivitamins
Refractory seizures Clobazam, secozam -
Petit mal epilepsy Encorate (Sod. valproate) Syrup i-vit B-complex
Grand mal, cortical focal, and psychomotor 
epilepsy
Phenytoin-SR (fentain) phenobarbitone Syrup i-vit
Infantile spasm Clonazepam
Cortical focal seizures Phenytoin (phenytoin) diazepam (secozam) Aciloc
Febrile convulsions Diazepam (calmpose)
Atonic seizures Clonazepam secozam Aciloc
Head injury Divalproex, carbin-SR, tegretol, secozam -
Typical seizure Clonazepam, secozam Syrup i-vit
Complex seizure Carbital, phenytoin Syrup i-vit Aciloc
Grand mal epilepsy Divalproex, secozam, libralex Aciloc
GTCS: Generalized tonic clonic seizures
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General principles for the symptomatic treatment of seizures with 
antiepileptic drugs:
•	 Choice	of	drugs	and	dose	is	according	to	the	seizure	type	and	need	
of individual patient. Early initiation of treatment, as each seizure 
episode increases the propensity to further attacks.
•	 Start	with	a	single	drug,	preferably	at	low	dose-gradually	increase	
dose till full control of seizures or side effects appear. If all reasonable 
monotherapy fails, use combinations.
•	 Therapy	should	be	as	simple	as	possible.	A	seizure	diary	should	be	
maintained.
•	 When	women	on	 antiepileptic	 therapy	 conceive,	 antiepileptic	
drugs should not be stopped. Discontinuation of therapy 
carries high-risk of status epilepticus. To avoid the chances of 
birth defects, an attempt to reduce the dose of drugs should be 
cautiously made.
Apart from these general principles of treatment, we concluded that 
the choice of antiepileptic drugs is primarily based on efficacy and 
effectiveness for the individual’s seizure type, but other patient-specific 
factors need to be considered which includes age, sex, childbearing 
potential, comorbidities, concomitant medications, and patient 
compliance [7]. The patient may discontinue the drug if they achieve 
seizure control after at least 2-4 years of seizure freedom and also after 
careful assessment of potential benefits versus the risk of relapse and 
related implications.
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